Society of Gynecologic Oncology Annual Meeting on Women's Cancer (SGO 2022)

Undergoing a minimally invasive radical hysterectomy leads to worse survival outcomes compared with open surgery in patients with early cervical cancer, according to final results of the LACC trial presented at SGO 2022.

In women with platinum-sensitive relapsed ovarian cancer without a deleterious or suspected deleterious germline BRCA1/BRCA2 mutation (non-gBRCAm), maintenance olaparib was well tolerated, according to the secondary safety results from the phase IIIb OPINION study presented at SGO 2022.

Maintenance treatment with selinexor improved progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer who had previously received first-line chemotherapy, particularly those with endometrioid histology and wild-type p53, according to a study presented at SGO 2022.

First-line maintenance therapy with niraparib at an individualized starting dose (ISD) improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer, according to results of the phase III PRIME study presented at SGO 2022.